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Crohn’s disease (CD) represents a highly debilitating disease of difﬁcult diagnosis and
increasing incidence. Serum protein proﬁling of early stage Crohn’s disease (ES) CD was
investigated in order to improve the comprehension of the very early pathologic mecha-
nisms and to support the difﬁcult diagnostic procedures currently available. Inﬂammatory
proteins and complement 3 chain C (C3c) were over-represented during ES CD, clusterin,
retinol binding protein, 1-microglobulin and transthyretin were under-represented. A C3c
isoform was found to be present only during ES CD. By now, lack of speciﬁc antibodies to
detect isoforms made it impossible to perform alternative validation.Crohn’s disease
2D electrophoresis
Comparative proteomics
C3c complement
Transthyretin
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). 
ological, endoscopic and histological studies [5]. The latter
involve invasive procedures, which are often a burden for
Open access under CC BY-NC-ND license.1.  Introduction
Crohn’s disease (CD), together with ulcerative colitis (UC), is
the most common form of inﬂammatory bowel disease (IBD)
[1]. CD is a chronic inﬂammatory condition of unknown aetiol-
ogy that can affect any portion of the digestive tract, but most
frequently the terminal ileum and/or the colon [2]. Genetic
factors, an abnormal immune response to microbial infec-
tions and unbalance in the gut-microbiota are thought to be
involved in disease pathogenesis [3,4].
∗ Corresponding author at: Istituto Sperimentale Italiano L. Spallanzani
Milano, Italy. Tel.: +39 02 50318138; fax: +39 02 50318171.
E-mail addresses: paola.roncada@guest.unimi.it, paola.roncada@gm
http://dx.doi.org/10.1016/j.euprot.2014.02.010
2212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf ofThe diagnosis and management of IBD still presents a num-
ber of challenges for treating physicians. The presence of
intestinal inﬂammation is a primary criterion for diagnosis
and differentiation from other diseases, no deﬁnitive diag-
nostic test exists as a gold standard for CD diagnosis, which
is made on the basis of history and physical examination,
supplemented with objective ﬁndings from laboratory, radi-, c/o DIVET, Università degli Studi di Milano, via Celoria 10, 20133,
ail.com (P. Roncada).
the patient. Consequently, in an attempt to overcome these
 European Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
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roblems, a number of laboratory markers for the disease have
een evaluated [6,7].
The presence of active gut inﬂammation in patients with
BD is associated with an acute phase reaction and the
igration of leukocytes in the gut [8,9]. This promotes the pro-
uction of a large number of proteins, detectable in serum
nd stools. In serum, elevated acute phase markers (e.g.
rythrocyte sedimentation rate, orosomucoid (alpha-1-acid
lycoprotein) and C-reactive protein, CRP) can be found. How-
ver, while these markers, and especially CRP, have been
hown to correlate with disease activity and prognosis of IBD,
heir speciﬁcity is insufﬁcient, and they may reﬂect general
nﬂammation [10–12]. Faecal calprotectin and lactoferrin are
he products of activated neutrophil cells and they are released
nto the faeces. They are more  speciﬁc biomarkers of IBD, and
ffer a promising way to conﬁrm intestinal inﬂammation, but
hey cannot differentiate between IBD and other intestinal
nﬂammations such as intestinal infections or non-steroidal
nti-inﬂammatory drug enteropathy [8–12]. Thus, the utility of
esting these biomarkers in routine clinical practice needs to
e explored further, including its cost. Serological studies eval-
ating antibodies against Saccharomyces cerevisiae (ASCA) and
erinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA)
ay provide adjunctive support for the diagnosis of CD and
ts differential diagnosis with UC, but they also suffer from a
ack of sensitivity and speciﬁcity [13–16].
The investigation of molecular mechanisms related to CD is
rucial to the development of new diagnostic and therapeutic
trategies. Although higher levels of acute phase proteins have
lready been well described in CD [17], a qualitative analysis of
soforms of these proteins during the disease state, and in par-
icular during the various stages of pathology, has never been
eported. Meuwis et al. [12] suggested the haptoglobin subunit
Hp 2) as a potential biomarker for the clinical phase of CD,
ut this study did not consider changes related to treatment
nd in the ES CD. Moreover, the role of protease inhibitors
s 1-antitrypsin (A1AT) and 1-antichymotrypsin (AACT)
as been reported to be important, in the pathophysiology
f this disease [18]. Crohn’s disease-related epithelial injury
nd ulceration are thought to be due to cytokine-mediated
lterations in the balance between matrix metalloproteinases
MMPs) and tissue inhibitors of MMPs  (TIMPs), resulting in
egradation of the lining of the gut [19]. We  therefore aimed
o investigate the proteomic proﬁle of the ES vs. AS CD in
omparison to HCs in order to explore the differential expres-
ion of acute phase proteins or protein isoforms characteristic
f the pathological status, according to disease duration and
reatment.
.  Materials  and  methods
.1.  Patients
he institutional ethics committee of Sacco Hospital of
ilan approved the experimental protocol (Protocol n◦39/07/83/06/AP, 13/04/2007). All subjects provided written
nformed consent before enrollment. Serum samples were
ollected from 13 healthy controls (HC), 8 early stage (ES)
D patients and 36 advanced stage (AS) CD patients for 3 ( 2 0 1 4 ) 48–59 49
comparative proteomic analysis. Of the 36 AS CD samples,
16 were excluded as they were receiving more  than one
anti-inﬂammatory drug at the time of serum collection, 20
were chosen to be included in this study. It has been decided
to avoid multiple drugs treatments to do not excessively
interfere with the serum proteome.
The diagnosis of CD was based on published international
criteria [5]. ES and AS CD were deﬁned according with the dura-
tion of the disease, as previously described [20–22], following
these criteria: Early = ﬁrst attack of CD in a patient with no
previous history of any gastrointestinal symptoms or surgery;
Advanced = CD in a patient with at least ﬁve years history
from the time of initial diagnosis and with persistent clinical
activity requiring immunosuppressors, immunomodulators,
steroids or surgery. ES CD patients had never received corti-
costeroids, antimetabolites or biological therapy and serum
was collected within 3 months from the diagnoses (median 1
month). We excluded any patient who had an immediate need
for surgery, severe comorbidity, documented chronic infec-
tion, a positive stool culture for pathogens, or a malignancy. AS
CD patients were treated or with systemic steroids, including
oral budesonide or prednisone, or with monoclonal antibodies
against TNF (i.e. inﬂiximab and certolizumab pegol), or with
oral immunosuppressors (i.e. azathioprine or methotrexate).
Table S1 has been added as supporting information and
summarizes the baseline demographic and clinical character-
istics of the enrolled patients.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2014.02.010.
2.2.  Samples
A single blood sample was taken from each HC/CD subject
after overnight fasting, and after 10–15 min  of rest. Blood
clotting was achieved by standing tubes vertically at room
temperature (22 ◦C) for 60 min. After blood clotting, samples
were centrifuged at 1500 × g for 10 min  at 4 ◦C and the super-
natants (serum) were stored in 1 mL  aliquots at -80 ◦C until
use.
2.3.  2D  electrophoresis
Three experimental replicates were performed for each sam-
ple to minimize technical gel-to-gel variation. The gels were
stained with coomassie G250, for evaluation of linear protein
expression and for mass spectrometric analysis. Immobiline
Dry strips (pH 3–10, length 18 cm,  GE-Healthcare) were rehy-
drated with 350 l buffer containing 8 M urea, 4% CHAPS,
65 mM DTT, 1% ampholine and 0.002% bromophenol blue
[23,24] for 14 h at room temperature. Serum samples were
defrosted and diluted in a buffer containing 8 M urea, 4%
CHAPS, 65 mM DTT, 1% ampholine pH 3.5–10 and 0.002% bro-
mophenol blue. 100 g of protein were loaded by cathodic cup
loading. Isoelectric focusing was performed using the Ettan
IPGphor III IEF System (GE Healthcare) with a total of 140 kVh.
Strips were equilibrated in a solution containing 6 M urea, 30%
glycerol, 2% SDS and 50 mM Tris–HCl (pH 8.8), with the addition
of 1% w/v DTT in the ﬁrst step, and 2.5% w/v  iodoacetamide
in the second step.
o m i c50  e u  p a o p e n p r o t e 
For the second dimension, proteins were separated by
SDS-PAGE on 10% polyacrylamide gels using Ettan Daltsix
(GE-Healthcare) according to the following procedure: 30 min
at a constant current of 12 mA  followed by 24 mA per gel
until the bromophenol blue front reached the bottom of the
gel. Gels were then stained with Coomassie G250 or silver
staining compatible with mass spectrometry [25]. Ultra nar-
row customized IPG strips (pH 4–5.5, length 13 cm [26,27]) were
rehydrated with 350 l rehydration buffer and 1 mg  of sample
protein was loaded by cathodic cup loading. For the second
dimension, proteins were separated by SDS-PAGE on 10% poly-
acrylamide gels using EttanDalt six (GE-Healthcare) according
to the following procedure: 30 min  at a constant current of
12 mA  followed by 24 mA  per gel until the bromophenol blue
front reached the bottom of the gel. Gels were then stained
with Coomassie G250 or MS  modiﬁed silver staining [25]. Ultra
narrow customized IPG strips (pH 4–5.5, length 13 cm [26,27])
were rehydrated with 350 l rehydration buffer and 1 mg  of
sample protein was loaded by cathodic cup loading.
For the second dimension, proteins were separated by
8–16% gradient–sodium dodecyl sulphate–polyacrylamide gel
electrophoresis using an Ettan Daltsix (GE-Healthcare). Gels
were stained using Coomassie G250.
2.4.  Image  analysis
All images were acquired using a PHAROS FX laser scanner
(Bio-Rad) at 100 m resolution. Gel images were imported into
Progenesis SameSpots (v4.5; Nonlinear Dynamics, Newcastle,
UK) for analysis [28].
All imported images were processed with Progenesis
SameSpots to check image  quality (saturation, dimension).
The aligned images were then automatically analyzed using
the 2D analysis module for spot detection, background sub-
traction, normalization, and spot matching, and all spots were
manually reviewed and validated to ensure proper detection
and matching.
2.5.  Statistical  analysis
Statistical analysis was performed using the Progenesis
Stats module on the log-normalized volumes for all spots.
Mann–Whitney test and one-way ANOVA were used to con-
ﬁrm the p value between different groups, p-values under 0.05
were considered statistically signiﬁcant. FDR (false discovery
rate) and power analysis were also calculated, q values <0.05
and power values >0.8 respectively were considered to be sig-
niﬁcant. Multivariate statistical analysis was carried out using
the Progenesis Stats module to perform principal components
analysis (PCA) [29].
2.6.  Protein  identiﬁcation  by  mass  spectrometry
2.6.1.  In  situ  digestion
Protein spots of interest were excised from the Colloidal
Coomassie-stained preparative gel. The excised spots were
ﬁrst washed with acetonitrile (ACN) and then with 0.1 M
ammonium bicarbonate. Protein samples were reduced by
incubation in 10 mM dithiothreitol for 45 min  at 56 ◦C. The
cysteine residues were alkylated by incubation in 55 mM s 3 ( 2 0 1 4 ) 48–59
iodoacetamide for 30 min at room temperature in the dark.
The gel particles were then washed with ammonium bicar-
bonate and ACN. Enzymatic digestion was carried out with
trypsin (12.5 ng/l) in 50 mM ammonium bicarbonate pH 8.5
at 4 ◦C for 1 h. The buffered solution was then removed and a
fresh aliquot of the enzyme/buffer solution was added for 16 h
at 37 ◦C. A minimum reaction volume, sufﬁcient to achieve the
complete rehydration of the gel was used. Peptides were then
extracted, washing the gel particles with 50 mM ammonium
bicarbonate and 0.1% triﬂuoroacetic acid (TFA) in 50% ACN at
room temperature, then lyophilized and resuspended in 30 l
of 0.1% formic acid/3% ACN for MS analysis.
2.6.2.  MALDI-TOF  Mass  spectrometry
Positive Reﬂectron MALDI-TOF mass spectra were recorded
on a Voyager DE STR instrument (Applied Biosystems,
Framingham, MA). The MALDI matrix was prepared by dis-
solving 10 mg of ˛-cyano-4-hydroxycinnamic acid in 1 ml  of
ACN/water (90:10 v/v). Typically, 1 l of matrix was applied to
the metallic sample plate and 1 l of each sample was then
added. Acceleration and reﬂector voltages were set up as fol-
lows: target voltage at 20 kV, ﬁrst grid at 95% of target voltage,
delayed extraction at 600 ns to obtain the best signal-to-noise
ratios and the best possible isotopic resolution with multi-
point external calibration using peptide mixture purchased
from Applied Biosystems. Each spectrum represents the sum
of 1500 laser pulses from randomly chosen spots per sample
position. Raw data were analyzed using the computer software
provided by the manufacturers and are reported as monoiso-
topic masses.
Database searches with the measured monoiso-
topic peptide masses were performed against the
Swiss Prot database using the peptide search MASCOT
(http://www.matrixscience.com). Search parameters were
typically set to 70 ppm maximal tolerance, one missed cleav-
age site for tryptic peptides allowed, and the modiﬁcations
accepted were carboamidomethylation with iodoacetamide of
cysteines and possible artefactual oxidation of methionines.
2.6.3.  NanoLC  mass  spectrometry
Tryptic peptides derived from each sample were analyzed by
nLC–MS/MS analysis using a 4000 Q-Trap (Applied Biosystems)
coupled to an 1100 nano HPLC system (Agilent Technolo-
gies). The samples were loaded on an Agilent reversed-phase
pre-column cartridge (Zorbax 300 SB-C18, 5 × 0.3 mm,  5 m)
at 10 l/min (A solvent 0.1% formic acid, loading time 5 min).
Peptides were separated on an Agilent reversed-phase col-
umn (Zorbax 300 SB-C18, 150 mm × 75 m, 3.5 m),  at a ﬂow
rate of 0.3 l/min with a 0–65% linear gradient in 60 min (A
solvent 0.1% formic acid, 2% ACN in MQ water; B solvent
0.1% formic acid, 2% MQ water in ACN). Nanospray source
was  used at 2.5 kV with liquid coupling, with a declustering
potential of 20 V, using an uncoated silica tip from NewObjec-
tives (O.D. 150 m, I.D. 20 m, T.D. 10 m).  Data were acquired
in information-dependent acquisition (IDA) mode, in which
a full scan mass spectrum was followed by MS/MS  of the 5
most abundant ions (2 s each). In particular, spectra acquisi-
tion of MS/MS analysis was based on a survey Enhanced MS
Scan (EMS) from 400 m/z to 1400 m/z at 4000 amu/s. This scan
mode was followed by an Enhanced Resolution experiment
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ER) for the ﬁve most intense ions and then MS2 spectra (EPI)
ere acquired using the best collision energy calculated on the
ases of m/z  values and charge state (rolling collision energy)
rom 100 m/z  to 1400 m/z at 4000 amu/s. Data were acquired
nd processed using Analyst software (Applied Biosystems).
LC MS  Data were analyzed using Analyst software (ver-
ion 1.4.1) and MS/MS  centroid peak lists were generated
sing the MASCOT.dll script (version 1.6b9). The threshold
f MS/MS  centroid peaks was taken to be 0.1% of the base
eak. MS/MS  spectra having less than 10 peaks were rejected.
S/MS  spectra were searched against the Swiss Prot database
sing the licensed version of Mascot 2.1 (Matrix Science),
fter converting the acquired MS/MS  spectra into the mas-
ot generic ﬁle format. The query was performed with the
aximal tolerance for parent masses of 200 ppm and a max-
mal tolerance for fragments of 0.2 Da, searching peptides on
+ and 3+ charge state. At the most two miss-cleavage for
ryptic peptides were allowed, and the modiﬁcations accepted
ere carboamidomethylation of cysteines as ﬁxed modiﬁca-
ions and oxidation of methionines and pyro-glu N-term Q
s variable post-translational modiﬁcations. The taxonomy
as restricted to Homo sapiens Spectra with a MASCOT score
25 were rejected. However, spectral data were manually val-
dated and contained sufﬁcient information to assign peptide
equence.
.6.4.  Western  blot  analysis
rotein extract from sera samples, 7 g and 5 g/lane were
oaded on a SDS-PAGE system 10%, transfer blotting was
chieved by a semi dry apparatus (NOVABLOT) on low ﬂu-
rescence PVDF. Membranes were incubated for 2 h using a
ommercial monoclonal antibody (NB100-64339, Novus Bio-
ogicals) speciﬁc against C3c complement and successively for
 h with a secondary antibody (A3562, SIGMA).
.  Results
ll samples were analyzed using 3–10 pH IPG strips and
btained data have been considered as main data. Further-
ore ultra narrow 4–5.5 [30] pH 2D electrophoresis have been
mployed to conﬁrm obtained data and to better annotate the
upposed speciﬁc protein isoforms.
.1.  HC  vs.  ES  CD
hen comparing ES CD and HC, image  analysis highlighted
0 proteins whose expression was signiﬁcantly altered in
he disease state, these proteins were successfully identiﬁed
y MS (Fig. 1a and b, Table 1). In particular, ˛1-antitrypsin
A1AT, 36.7% higher in ES CD), ˛1-antichymotrypsin (AACT,
0.2% higher in ES CD), and complement 3 fragment C (C3c,
70% higher in ES CD) were up-represented, haptoglobin
HPT, 32% higher in ES CD) expression showed a tendency to
p-regulation (p = 0.08) (Fig. 1a).On the other hand, RETBP, CLUS, AMBP, and TTHY were sig-
iﬁcantly under-represented in ES CD compared with HC, with
evels 49.8%, 51%, 74% and 56.6% lower (p ≤ 0.05), respectively
Fig. 1b).
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Fig. 1 – (a) Up-represented serum proteins in ES CD (n = 8) and HCs (n = 13). A1AT (1-antitrypsin): HCs (2.96 ± 0.54) vs. CD
(4.05 ± 0.65); AACT (1-antichymotrypsin): HCs (0.55 ± 0.15) vs. CD (0.83 ± 0.22); HPT (haptoglobin): HCs (4.30 ± 1.03) vs. CD
(5.67 ± 0.86); C3c (complement 3 fragment c): HCs (0.17 ± 0.09) vs. CD (0.63 ± 0.13) (*p ≤ 0.05). (b) Down-represented serum
proteins in ES CD (n = 8) and HCs (n = 13): RETBP (retinol binding protein): HCs (0.12 ± 0.03) vs. CD (0.06 ± 0.03); CLUS
(clusterin): HCs (0.35 ± 0.06) vs. CD (0.17 ± 0.03); AMBP (1-microglobulin): HCs (0.067 ± 0.016) vs. CD (0.017 ± 0.012); TTHY
(transthytretin): HCs (0.78 ± 0.17) vs. CD (0.34 ± 0.1). *p < 0.05 for Mann Whitney test carried out for each sampling data point
between HC and CD proteins.Furthermore, two proteins apparently absent in HC sam-
ples were identiﬁed in ES CD samples: one isoform of
transthyretin at pI 4.7 and one isoform fragment of comple-
ment C3c at pI 4.9 (Fig. 2). Both isoforms were found in 3–10 and
4–5.5 pH range experiments, as well as they were successfully
identiﬁed by MALDI TOF and nLC–MS/MS analysis.
3.2.  ES  CD  vs.  AS  CD
As shown in Fig. 3a, the proteins over-represented during the
ES of CD did not maintain higher relative levels during the
AS of the disease, and their expression was similar to HC.
Notable exceptions to this, however, were C3c complement
fragment and, to a greater extent, haptoglobin (C3c p = 0.024;
HPT p = 0.01). Proteins which were under-represented during
the ES of CD, were also observed to return to normal (HC) lev-
els in AS CD (Fig. 3b). Notably, no differences were observed
within the AS CD patient group according to the type of
anti-inﬂammatory treatment (data not shown).3.3.  PCA  analysis  of  all  groups
To provide evidence for the differences between serum sam-
ples, multivariate unsupervised PCA analysis was performed.Fig. 4 represents the biplot of the ﬁrst two principal compo-
nents (PC).
The biplot showed an effective separation of samples in
two classes: ES CD samples (pink, negative scores of PC1), and
HCs (cyan, positive scores of PC1). Spots that contribute to dif-
ferences between the two groups are present as loadings in
the PCA plot (spot numbers, Fig. 4) and conﬁrm the results
obtained by non-parametric univariate analysis.
Fig. 5 shows the biplot which also includes samples from
CD AS. The graph highlights the similarity between the AS CD
(violet) and HCs (cyan) that would be included in the same
group using this analysis. This conﬁrms that in AS CD protein
expression returns similar to control values.
A validation of the C3 fragment proﬁle has been attempted
using commercial monoclonal antibody NB100-64339, Novus
Biologicals. Such a validation has been performed in the early
stage Crohn’s disease samples as considered more  signiﬁ-
cant (Fig. 6). Unfortunately the speciﬁc fragment isoform of
C3 complement highlighted in the 2DE was not detected by
this antibody which is recognizing a protein band at 115 kDa
supposedly associated with the intact C3 protein. This band
shows an overall trend similar to of C3c complement isoform,
detected by the 2DE, however these results, do not show a
statistically signiﬁcant differential expression but only a sug-
gestive proﬁle.
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Fig. 2 – Details of 2-D map  (pI 4.7–5.6; kDa 45–30). 1 = complement 3 fragment c; 2 = transthyretin; 3 = transthyretin isoform pI
4.7; 4 = complement 3 fragment c isoform pI 4.9.
Fig. 3 – Expression proﬁling of up-represented proteins during AS of Crohn’s disease: only HPT and C3c complement were
u ) (*p ≤
4
T
pp-represented compared to HCs (HPT p = 0.01; C3c p = 0.024.  Discussion
he differential protein display was evaluated in ES CD
atients vs. HC and in AS CD patients vs. ES CD. 0.05).4.1.  HC  vs.  ES  CD
Image  and multivariate (PCA) analysis of 2D maps showed
an overexpression of ˛1-antitrypsin, ˛1-antichimotrypsin and
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Fig. 4 – Biplot of the ﬁrst two components of the principal component analysis of HCs and ES CD. Ovals indicate the areas
 spowhere the data points of the two groups are distributed pink
complement factor 3 chain c during ES CD (Fig. 1a) in
comparison to HC, haptoglobin showed a over-represented
trend. On the other hand, clusterin, retinol binding pro-
tein, ˛1-microglobulin and transthyretin (Fig. 1b) were
under-represented. These are mostly inﬂammation-related
proteins that have already been described during Crohn’s dis-
ease. However, this is an innovative study because of the
presence of a rare group of Crohn’s disease patients that
have been investigated during the ES of this disease. The
analysis of the serum proteome of this particular pool of sam-
ples revealed, as described below, the presence of differential
expression of the described proteins and their isoforms.
4.2.  ES  CD  vs  AS  CD
Obtained results highlighted the presence of important dif-
ferences between the proteomic proﬁles of HC and ES CD,
however, the relative levels of these proteins came back to
levels similar to HC in AS CD patients (Fig. 3). Different
immune activation patterns have been previously described
for T-cell responses in a study in children, where variations
in mucosal T-cell immune regulation during the course of
human IBD were observed [20]. In particular, at the onset of
CD, mucosal T cells appear to mount a typical Th1 response
that resembles an acute infectious process, but this response
is lost with progression to AS CD, suggesting that patients with
the initial manifestations of IBD may represent an ideal pop-
Fig. 5 – Biplot of the ﬁrst two components of the principal compo
where the data points of the two groups are distributed pink spots: ES CD, cyan spots: HCs.
ulation in which immunomodulation has optimal therapeutic
efﬁcacy.
Moreover, the overexpression of some proteins in the ES CD
may reﬂect their potential role in disease pathogenesis accord-
ing to the particularities of their functions in the inﬂammatory
cascade, or simply be an aspeciﬁc marker of inﬂammatory
activation.
Differentially represented proteins and isoforms dur-
ing ES and AS CD in comparison to HC: ˛1-antitrypsin
and ˛1-antichymotrypsin are protease inhibitors and posi-
tive acute-phase proteins whose plasma concentrations are
increased as a result of inﬂammation. During acute phase
response, overexpression of these two proteins is crucial in
the irreversible inhibition of protease activity. Both proteins
are synthesized primarily in the liver, but isoforms of A1AT
have been previously shown to be present also in gut Paneth
cells [31], and variable associations have been found between
A1AT levels or polymorphisms and CD, with conﬂicting results
[32–34]. Notably, an excess of tissutal protease inhibitors like
A1AT has been described [31] and this was associated with
a disturbance in the normal processing of antimicrobial pep-
tides, like defensins, which then allows increased exposure of
the intestinal mucosa to luminal micro-organisms [35], trig-
gering an excessive immune activation in IBD. On the other
hand, the downregulation of these antiproteases, that was
observed in AS CD, may suggest new mechanisms of disease
control by the various anti-inﬂammatory treatments used or
changes in the mechanisms of immune activation during the
nent analysis of HCs and ES/AS CD. Ovals indicate the areas
ts: ES CD samples. Violet spots: AS CD, cyan spots: HCs.
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Fig. 6 – Immunoblotting of the C3c. (a) One dimensional
electrophoresis (coomassie staining). (b) One dimensional
immunoblotting with 7 g per lane protein load. (c) One
dimensional immunoblotting with 5 g per lane protein
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example, to study if impaired protection from oxidative stress,oad.
dvanced phases of the disease. As described before, recent
ndings highlighted that an impaired metabolism of proteases
nd proteases inhibitors could be linked to the etiopathogen-
sis of this disease [19].
.3.  Complement  C3c
ike other acute phase proteins, complement C3c is
ver-represented. This data conﬁrms results from previ-
us studies [36]. Complement-derived proteolytic products
ediate functions which contribute to pathogen disruption
nd elimination [37]. However, the inappropriate activation of
he complement system has been involved in pathogenetic
echanisms of immunological and inﬂammatory diseases,
ncluding IBD, as shown in several studies [17,38–49]. The
entral role of complement component 3 (C3) is due to the
omplexity of the functional regulation of its fragments,
ncluding the major fragment, C3b, which anchors the con-
ertase assembly effecting activation of fragments C3 and C5. 3 ( 2 0 1 4 ) 48–59 55
C3c is a fragment derived from the proteolysis of C3b; C3c
over-representation was found not only during the ES CD but
also during AS disease, irrespective of various treatments,
suggests a dysregulated complement metabolism that could
be related to disease pathogenesis and to the maintenance of
gut inﬂammation. Recent metaproteomic studies suggest the
possibility to evaluate the differences between the normal and
the pathological microbiota [50]. Furthermore, image  analysis
revealed a C3c isoform at pI 4 [50]. Furthermore, image  anal-
ysis revealed a C3c isoform at pI 4.9 apparently missing in HC
samples, further highlighting the speciﬁc role of the comple-
ment system in CD immune activation as well as the need to
better explore the role of this isoform. A putative explanation
of the role of the complement system in other autoimmune
pathologies have already been proposed [30] but the provided
explanation does not include the description of the role or
the provenience of C3c fragment. However the differential
representation of such a C3 isoform may be interesting, we
could not independently validate such an evidence by the use
of an immunochemical method with commercial antibodies.
Only a trend proﬁle of the intact Complement C3 protein could
be detected. Such a partial result may be due to a number
of factors affecting the superimposition of 2DE data with
classical Western blot detection. The problem of validation
of speciﬁc isoforms of proteins that are signiﬁcantly different
in 2D electrophoresis is a question regarding the availability
of epitope qualiﬁed and validated reagents. Also in this
case, there are no commercial antibodies available against a
speciﬁc isoforms and the commercial products are directed
to a speciﬁc undisclosed sequence of the entire proteins.
4.4.  Clusterin
The present study shows also that clusterin, retinol binding
protein, ˛1-microglobulin and transthyretin are underrep-
resented during ES CD. An over-expression of clusterin is
reported in a wide variety of models of stress and disease,
including withdrawal of growth factors and exposure to toxic
agents [51]. Moreover clusterin expression [51]. Moreover
clusterin expression increases in humans usually during
intense oxidative stress, although this phenomenon is not
observed in rheumatoid arthritis [52]. These ﬁndings suggest
a possible role for clusterin in protecting cells from oxidative
stress during pathological status and inﬂammatory response.
Accordingly, strongly enhanced levels of clusterin were pre-
viously described in the ileum of CD patients, correlating
with disease activity [53]. Increased level of clusterin dur-
ing ES CD is therefore expected to protect tissues against
oxidative stress damage caused by inﬂammation [54,55]. The
under-representation of clusterin in ES CD observed in our
study, is therefore an unexpected result, and warrants further
investigation to explore the etiopathogenic implications; forcould be responsible for tissue injury and impaired mucosal
barrier. The result may also suggest potential analogies
between CD and rheumathoid arthritis pathogenesis [56].
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4.5.  ˛1-Microglobulin
˛1-Microglobulin is an immunosuppressive plasma protein
synthetized by the liver. The down-regulation observed in this
study has never been reported before and deserves further
investigation as it may reﬂect a loss of immunoregulatory
function which could inﬂuence the balance between pro- and
anti-inﬂammatory pathways of immune response. However it
has been interestingly documented a considerably increased
excretion of ˛1-microglobulin in patients affected by Crohn’s
disease. Its increased excretion is so high to induce scientists
to speculate ˛1-microglobulin in urine as putative biomarker
for the evaluation of IBD activity index [57].
Retinol binding protein (RBP) is synthesized primarily in the
liver, and requires retinol binding to trigger its secretion
[58,59]. In vivo, RBP binds the larger protein, transthyretin,
while in vitro one tetramer of TTR binds two molecules of
retinol binding protein. However, the concentration of RBP in
plasma is limiting and the complex isolated from serum is
composed of both TTR and RBP (in a one to one stoichiometry)
with a resultant molecular mass of about 80 kDa. The bind-
ing of RBP to TTR prevents extensive loss of the low molecular
weight RBP through glomerular ﬁltration and may also restrict
free partitioning of RBP into the intercellular space outside the
vascular system [58,60,61]. Retinol binding protein is a vitamin
A carrier; its decrease in CD has been previously described [62]
as a sign of intestinal malabsorption. The most interesting
characteristic of RBP is due to its common positive correla-
tion with systemic inﬂammation that is the phenomenon that
characterizes CD [63]. But surprisingly, obtained results, con-
ﬁrmed its down-regulation during ES CD in spite of what was
expected. However a recent study by Keicho and colleagues
found RBP decreased in patients with tuberculosis [64]. This
experimental evidence suggests again a putative microbial
implication in the pathogenesis of CD particularly if consider-
ing that Mycobacterium avium subsp. paratuberculosis has been
often described as the putative cause of CD [65] and could be
found in cow milk for human consumption [66]. Moreover par-
ticular attention needs to be paid to microbial pathogens due
to the recent evidences in the ﬁeld of multidrug resistance [67].
4.6.  Transthyretin
TTR is mainly synthesized by the liver and then secreted
into the circulation. It is normally considered a negative
acute-phase protein as well as a nutritional index [68]; our
results match favourably with previous studies showing
decreased levels of TTR in active CD [18], as well as its
increase after effective treatment with inﬂiximab [69]. Its
concentration was found to be decreased also in rheumatoid
arthritis conﬁrming the already described analogies between
this two pathologies [70]. In ES CD it has been found an
isoform at pI 4.7. The presence of this isoform only in ES CD
could be linked to a putative PTM of this protein linked to the
pathological status. The putative role of TTR as biomarker
has been already described for other pathologies [71]. s 3 ( 2 0 1 4 ) 48–59
5.  Conclusion
Our collected evidences highlighted a differential protein dis-
play of several serum proteins in ES CD patients. In addition
it was found a transthyretin isoform (pI 4.7) and C3c fragment
isoform (pI 4.9) which has not been described before in type
of clinical samples. These isoforms could help to explain the
molecular changes observed during the clinical phase of CD
and in particular the role of C3c complement in the com-
plement cascade activation and in the disease progression.
The C3c isoform is of particular interest as it was still rep-
resented in 78% of AS CD patients after anti-inﬂammatory
therapies. This observation may indicate that other factors (for
example, microbial components) could still play an important
role in the advanced phases of the disease. In particular it is
important to quote that many  other proteomic studies have
investigate the acute phase proteins in other diseases similar
to CD as rheumatoid arthritis [72]. None of this studies per-
formed on serum described an augmented expression of C3c
complement as it was found in this study [70]. Another study
conducted by Cylwik and colleagues describes the analysis of
all serum acute-phase proteins during the course of rheuma-
toid arthritis highlighting that C3 complement concentration
was not inﬂuenced by the disease activity [73]. Moreover even
if C3 complement has been described as autoantigen dur-
ing IBD [74], the over-representation of C3c has never been
described during this kind of pathologies. The relevance of
C3 complement and isoforms as putative biomarker for other
pathologies has also been described highlighting the relevance
of further studies on this topic [75–77]. All this experimen-
tal evidences could suggest that C3c proteolytic isoforms
expression in Crohn’s disease could be disease speciﬁc and
encourages further investigation in wider populations [78] in
particular in the light of the difﬁculties actually encountered in
the diagnoses of this pathology. Although the detection of the
described isoforms could represent a difﬁcult task since the
currently available commercial antibodies are not recogniz-
ing this isoforms. The development of new generation afﬁnity
binders isoform speciﬁc will represent a key milestone for the
construction of diagnostic tests for the early phases of this
pathology.
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